Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: re3 who wrote (84419)	10/22/2000 12:20:43 PM
From: Knighty Tin	Read Replies (2) \| Respond to of 132070

Ike, Duramed got creamed for having "lousy" sales up 100%. Still love it. Vaso, no change in fundamentals and little in price, so no update needed. It is still a buy. Celera is definitely in a buy zone, though solid profits are for the patient only. In that type of position, any down move in the market gets exaggerated in this stock. I like it, but it is not for the squeamish. The same could be said for Ligand, though the price is much nicer there. You have to have faith for this one and I consider it something of a guilty pleasure. The co. has many factors I look for in my put stocks, but the science is so good that it overwhelms them to find a place in my portfolio. I watch it closer than most, but every portfolio needs a little hypocrisy in it. <g> Once again, though, only 10% of my total portfolio is long stocks, so look at my responses with that background.